Revive Therapeutics
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Director Ct Ste 105, Vaughan, Ontario,...Phone Number
(888) 901-0036Website
www.revivethera.comRevenue
<$5 MillionStock Symbol
RVVIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Revive Therapeutics
Revive Therapeutics is a life sciences company dedicated to the research and development of therapeutics and diagnostics for infectious diseases, mental health, and rare disorders. The company is focusing on drug development efforts that leverage various FDA regulatory incentives, including Emergency Use Authorization and Orphan Drug designations. Currently, Revive is exploring Bucillamine for potential treatments related to public health emergencies and rare inflammatory disorders, while also advancing Psilocybin-based therapeutics. Their innovative biosynthetic platform aims to efficiently produce natural products, enhancing their therapeutic offerings.Explore more
Revive Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Revive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Revive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Revive Therapeutics has new funding data
Check if Revive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Revive Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Revive Therapeutics
Check out if Revive Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Revive Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Revive Therapeutics launches new products
Recommended Actions
Find VP level buyers at Revive Therapeutics
Find more new buyers
Compare Similar Companies to Revive Therapeutics
Compare insights from companies similar to Revive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Revive Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Revive Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Revive Therapeutics.
Revive Therapeutics Tech Stack
A closer look at the technologies used by Revive Therapeutics
See more technologies
Revive Therapeutics News & Media
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield ResearRevive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.Revive Therapeutics Announces Extension of Proposed Private Placement
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is extending is previously announced private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000. Revive closed a first tranche of the private placement inRevive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.0
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Revive Therapeutics
Sign Up For FreeTo access detailed company insights
Revive Therapeutics is a life sciences company dedicated to the research and development of therapeutics and diagnostics for infectious diseases, mental health, and rare disorders. The company is focusing on drug development efforts that leverage various FDA regulatory incentives, including Emergency Use Authorization and Orphan Drug designations.... Read More
